Analysts Set Elanco Animal Health Incorporated (NYSE:ELAN) Price Target at $15.83

Elanco Animal Health Incorporated (NYSE:ELAN) has earned a consensus recommendation of “Hold” from the seven brokerages that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $15.83.

A number of brokerages recently weighed in on ELAN. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Leerink Partners started coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Morgan Stanley cut their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Barclays lowered their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Finally, Stifel Nicolaus cut their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday, February 21st.

Elanco Animal Health Trading Up 0.3 %

Shares of ELAN stock opened at $10.84 on Friday. The company has a market capitalization of $5.36 billion, a PE ratio of 27.09, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. Elanco Animal Health has a 52-week low of $10.20 and a 52-week high of $18.80. The business’s fifty day moving average is $11.68 and its 200 day moving average is $12.97. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.08 earnings per share. On average, equities research analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

A number of large investors have recently bought and sold shares of the stock. DDD Partners LLC purchased a new stake in shares of Elanco Animal Health during the fourth quarter valued at approximately $5,974,000. Geode Capital Management LLC boosted its stake in shares of Elanco Animal Health by 0.8% during the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after purchasing an additional 65,303 shares during the period. Atom Investors LP boosted its stake in shares of Elanco Animal Health by 310.3% during the third quarter. Atom Investors LP now owns 345,855 shares of the company’s stock valued at $5,081,000 after purchasing an additional 261,559 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of Elanco Animal Health by 24.0% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after purchasing an additional 209,734 shares during the period. Finally, Wellington Management Group LLP boosted its stake in shares of Elanco Animal Health by 19.2% during the third quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock valued at $58,875,000 after purchasing an additional 646,522 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.